State Key Laboratory of Respiratory Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Medical University, Guangzhou, China.
Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
J Med Virol. 2022 Sep;94(9):4378-4382. doi: 10.1002/jmv.27815. Epub 2022 May 4.
Respiratory syncytial virus (RSV) is the major cause of pneumonia and bronchiolitis in infants and young children and mediates substantial morbidity and mortality in the elderly and immunocompromised globally. The development of a safe and effective RSV vaccine and an optimized neutralizing antibody (NAb) with strong virus-neutralizing activity is appealing. To gain some detailed knowledge of the humoral immune response to RSV subgroup A (RSV-A) and RSV-B, we investigated the seroprevalence of pre-existing NAbs by using the microneutralization assay in healthy adult from Guangzhou, southern China. We found that the overall seropositive rate was 84.86% for anti-RSV NAbs. Furthermore, the seropositive rates were 68.47% and 73.61% for anti-RSV-A NAbs and anti-RSV-B NAbs, respectively. In addition, although the seropositive rates and NAb levels were not associated with the blood type, type AB individuals displayed higher seropositive rates for anti-RSV-A NAbs with high titer (≥ 288) and anti-RSV-B NAbs, especially those with moderate titer (≥ 72 to < 288). The seropositive rates and titers were comparable between anti-RSV-A NAbs and anti-RSV-B NAbs in the AB blood type group. Interestingly, only when the NAb titer of the serum to RSV-A was not less than 288, was it not less than 18 to RSV-B, and vice versa. These results would be helpful for a better understanding of the human serum NAb responses to RSV-A and RSV-B.
呼吸道合胞病毒（RSV）是婴儿和幼儿肺炎和细支气管炎的主要病因，也是全球老年人和免疫功能低下者发病率和死亡率高的主要原因。开发安全有效的 RSV 疫苗和具有强大病毒中和活性的优化中和抗体（NAb）是吸引人的。为了更详细地了解呼吸道合胞病毒 A 亚群（RSV-A）和 RSV-B 的体液免疫反应，我们使用微量中和试验调查了来自中国南方广州的健康成年人中预先存在的 NAb 的血清阳性率。我们发现，针对 RSV 的 NAb 的总血清阳性率为 84.86%。此外，针对 RSV-A 的 NAb 和针对 RSV-B 的 NAb 的血清阳性率分别为 68.47%和 73.61%。此外，尽管血清阳性率和 NAb 水平与血型无关，但 AB 型个体对高滴度（≥288）和中等滴度（≥72 至 <288）的针对 RSV-A 的 NAb 和针对 RSV-B 的 NAb 的血清阳性率更高。AB 血型组中针对 RSV-A 的 NAb 和针对 RSV-B 的 NAb 的血清阳性率和滴度相当。有趣的是，只有当血清中针对 RSV-A 的 NAb 滴度不低于 288 时，针对 RSV-B 的 NAb 滴度才不低于 18，反之亦然。这些结果将有助于更好地了解针对 RSV-A 和 RSV-B 的人血清 NAb 反应。
